Showing 7571-7580 of 23122 results for "".
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
https://reachmd.com/programs/cme/surgical-crossroads-practical-considerations-for-optimizing-treatment-in-tgct/48907/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Diagnosing Myasthenia Gravis: The Impact of Social Media
https://reachmd.com/programs/clinicians-roundtable/diagnosing-myasthenia-gravis-the-impact-of-social-media/27071/Explore how social media can help expedite myasthenia gravis diagnosis by engaging undiagnosed patients and raising awareness about symptoms.Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
https://reachmd.com/programs/cme/clinical-evidence-in-focus-interpreting-data-on-systemic-therapy-targeting-csf1r/48906/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.When and Why to Use CAC Scoring
https://reachmd.com/programs/cme/when-and-why-to-use-cac-scoring/35818/Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcUnlocking the CSF1R Code: Targeted Pathways and Tailored Choices
https://reachmd.com/programs/cme/unlocking-the-csf1r-code-targeted-pathways-and-tailored-choices/48905/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.MS Treatment Decisions: When to Discontinue Disease-Modifying Therapies
https://reachmd.com/programs/neurofrontiers/ms-treatment-decisions-when-to-discontinue-disease-modifying-therapies/17929/Given risk factors involving disease-modifying therapies for MS, stable patients may want to discontinue them. Here’s how to approach this decision.COPD Care: Examining the Clinical Burden and Treatment of Suboptimal PIF
https://reachmd.com/programs/frontlines-copd/copd-care-examining-the-clinical-burden-and-treatment-of-suboptimal-pif/35539/A recent study found that more than 50 percent of COPD patients who were admitted to the hospital after experiencing an acute exacerbation had suboptimal peak inspiratory flow (PIF). Despite this, patients were consistently sent home on a dry powder inhaler, putting them at risk of repeated hospitalBeyond the Scalpel: When TGCT Surgery Isn’t the Solution
https://reachmd.com/programs/cme/beyond-the-scalpel-when-tgct-surgery-isnt-the-solution/48904/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Understanding the Role of Vitamin B12 in COPD
https://reachmd.com/programs/clinicians-roundtable/vitamin-b12-copd/54189/Up to a third of patients with chronic obstructive pulmonary disease (COPD) may have vitamin B12 deficiency—a factor closely linked to cardiovascular health, systemic inflammation, and functional capacity. Dr. Nasibul Alam, an internal medicine resident at the Rosalind Franklin University of MedicinIL-17A Inhibition and the Stress Response in Psoriasis
https://reachmd.com/programs/Audioabstracts/il-17a-inhibition-stress-response-psoriasis/39684/When prescribing secukinumab, we focus on IL-17A blockade to clear psoriatic plaques—but could this targeted therapy also influence the body’s stress system? Join Ryan Quigley as he walks through a 16-week clinical study exploring how IL-17A inhibition affects the hypothalamic–pituitary–adrenal axis